Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma

Abstract

Osteosarcoma is the most common primary malignant bone tumor with a high metastatic potential. Nowadays, there is a lack of new markers to identify prognosis of osteosarcoma patients with response to medical treatment. Recent studies have shown that hematological markers can reflect to some extent the microenvironment of an individual with the potential to predict patient prognosis. However, most of the previous studies have studied the prognostic value of a single hematological index, and it is difficult to comprehensively reflect the tumor microenvironment of patients. Here, we comprehensively collected 16 hematological markers and constructed a hematological prognostic scoring system (HPSS) using LASSO cox regression analysis. HPSS contains many indicators such as immunity, inflammation, coagulation and nutrition. Our results suggest that HPSS is an independent prognostic factor for overall survival in osteosarcoma patients and is an optimal addition to clinical characteristics and well suited to further identify high-risk patients from clinically low-risk patients. HPSS-based nomograms have good predictive ability. Finally, HPSS also has some hints for immunotherapy response in osteosarcoma patients.

The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients

“…However, despite these advancements, there is still much to be done in terms of improving diagnosis and treatment options for osteosarcoma. For instance, the identification of biomarkers that can predict treatment response and patient outcome would greatly aid in tailoring treatment to individual patients (13)(14)(15).…”

“…Importantly, these assessments are routinely obtained through standard clinical tests and often do not require additional testing costs. Among these, NLR research is the most extensive and has been incorporated into the latest guidelines for the diagnosis and treatment of urological system tumors (15,(23)(24)(25)(26). Although most studies examining the role of NLR in cancer have focused on baseline values, recent evidence suggests that the dynamic changes in NLR during treatment may be more informative in predicting patient prognosis (27)(28)(29).…”